Genetic studies have thus far identified a limited number of loci associated with human longevity by applying age at death or survival up to advanced ages as phenotype. As an alternative approach, one could first try to identify biomarkers of healthy ageing and the genetic variants associated with these traits and subsequently determine the association of these variants with human longevity. In the present study, we used this approach by testing whether the 35 baseline serum parameters measured in the Leiden Longevity Study (LLS) meet the proposed criteria for a biomarker of healthy ageing. The LLS consists of 421 families with long-lived siblings of European descent, who were recruited together with their offspring and the spouses of the offspring (controls). To test the four criteria for a biomarker of healthy ageing in the LLS, we determined the association of the serum parameters with chronological age, familial longevity, general practitioner-reported general health, and mortality. Out of the 35 serum parameters, we identified glucose, insulin, and triglycerides as biomarkers of healthy ageing, meeting all four criteria in the LLS. We subsequently showed that the genetic variants previously associated with these parameters are significantly enriched in the largest genome-wide association study for human longevity.
Introduction
Chronological age is the main risk factor for many diseases. However, the rate of ageing is different between persons and some individuals become very old and seem to delay or even escape age-related disability (Christensen et al., 2008; Terry et al., 2008) . Hence, by investigating longevity as a trait, we may be able to identify mechanisms that promote healthy ageing and protect against age-related disease. Since human longevity is heritable and clusters in families (Perls et al., 2000; Westendorp et al., 2009) , genetic determinants of healthy ageing have been investigated using genome-wide association studies (GWAS). Thus far, only a limited number of longevity loci have been identified, i.e. TOMM40/APOE/APOC1, FOXO3A and chromosome 5q33.3 (Broer et al., 2015; Deelen et al., 2014a) . Together, these loci only explain a small part of the heritability of human longevity, which has been estimated to be around 25% (Herskind et al., 1996; Hjelmborg et al., 2006) and is assumed to be explained by many genes with relatively small effects (Finch and Tanzi, 1997; Kirkwood et al., 2011) . The lack of identified loci is most likely caused by the small sample size of the GWAS, which is attributable to limited availability of the studied outcomes, i.e. prospective survival or survival up to advanced ages, i.e. above 90 or 100 years (exceptional longevity).
As an alternative approach, one could first try to identify biomarkers of healthy ageing (Sprott, 2010) and the genetic variants associated with these traits and subsequently determine the association of these variants with longevity. We have previously proposed four criteria for a quantitative parameter that, we think, need to be fulfilled before Experimental Gerontology 82 (2016) 
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being considered a biomarker of healthy ageing (Deelen et al., 2013) . In short, a biomarker of healthy ageing should show an association with (1) chronological age, (2) familial propensity for longevity, (3) known health parameters, and (4) morbidity and/or mortality (Box 1). Thus far, biomarker research has identified several potential biomarkers of healthy ageing, such as glucose and free triiodothyronine (fT3) serum levels, CDKN2A (p16) gene expression, leukocyte telomere length (LTL), and gait speed (Deelen et al., 2013; Njajou et al., 2009; Shiels, 2010) . Some of these potential biomarkers of healthy ageing have been reported to associate with mortality, while others show a crosssectional difference between young and old individuals, and therefore seem useful. However, previous studies for biomarkers of healthy ageing did not yet consistently investigate all four criteria or the studied biomarkers did not meet all criteria (e.g. LTL met three of the criteria, but was unable to discriminate individuals based on their familial propensity for longevity (Deelen et al., 2014b) ). Identified biomarkers may be studied in GWAS with a larger sample size than GWAS for longevity. A similar approach has previously been applied in studies of complex diseases, such as type 2 diabetes and Alzheimer's disease, in which GWAS on endophenotypes successfully identified loci that play a role in progresses underlying these diseases (Cruchaga et al., 2013; Ingelsson et al., 2010) . Hence, we will apply the same approach to identify loci contributing to human longevity. In this study, we first test whether all available serum parameters in the Leiden Longevity Study (LLS) (Schoenmaker et al., 2006) meet the four criteria for a biomarker of healthy ageing. The LLS consists of 421 long-lived families (two generations), which have been followed for over 10 years. This enables us to test potential biomarkers for their association with mortality in two generations, i.e. the nonagenarians and the combined group of their offspring and controls. In addition, we will compare the levels of potential biomarkers between middle-aged members of long-lived families and controls. We previously showed that long-lived family members display a decreased prevalence of age-related diseases in comparison to controls Bos et al., 2013) . Hence, they are considered "healthy agers". Subsequently, we tested whether there is a significant enrichment of genetic loci contributing to the identified biomarkers of healthy ageing in a GWAS for human longevity in individuals of European descent, which is currently the largest GWAS for human longevity that has been performed (Deelen et al., 2014a) .
Materials and methods

Study population
The LLS consists of 421 long-lived families of European descent. Families were included if at least two long-lived siblings were alive and fulfilled the age criterion of 89 years or older for males and 91 years or older for females, representing b0.5% of the Dutch population in 2001 (Schoenmaker et al., 2006) . In total, 944 long-lived proband siblings (mean age = 94 years, range = 89-104), 1671 offspring (mean age = 61 years, range = 39-81) and 744 spouses thereof (mean age = 60 years, range = 36-79) were included. In the LLS, the spouses are considered controls. DNA from the LLS was extracted from white blood cells at baseline using conventional methods and genotyping was performed with Illumina Human660W-Quad and OmniExpress BeadChips (Illumina, San Diego, CA, USA) (Deelen et al., 2014a) . In this study, we only used the individuals for which the identity was confirmed after genotyping.
Biochemical measurements
All standard serum measurements were performed in non-fasting venous blood samples using fully automated equipment.
Glucose, fructosamine, high-sensitivity C-reactive protein (CRP), free fatty acids (FFA), triglyceride, and total and high-density lipoprotein (HDL) cholesterol levels were measured on the Hitachi Modular P 800. fT3, free thyroxine (fT4), and thyroid stimulating hormone (TSH) levels were measured on the Modular E170, while parathyroid hormone (PTH) and 25(OH) vitamin D3 were measured on the Cobas e 411 analyzer (all from Roche, Almere, the Netherlands) (Noordam et al., 2012; Rozing et al., 2009; Rozing et al., 2010; Rozing et al., 2011) . LDL cholesterol levels were calculated using the Friedewald formula (Friedewald et al., 1972) and set to missing if plasma triglyceride levels exceeded 4.52 mmol/L.
Insulin, insulin-like growth factor 1 (IGF-1), and insulin-like growth factor-binding protein 3 (IGFBP3) levels were measured on the Immulite 2500 (DPC, Los Angeles, CA, USA) ). For calculation of the IGF-1/IGFBP3 molar ratio we used the following formula:
Triglyceride levels and low-density lipoprotein (LDL) and highdensity lipoprotein (HDL) particle sizes and concentrations were measured using proton nuclear magnetic resonance (NMR) spectroscopy (LipoScience Inc., Raleigh, NY, USA) (Vaarhorst et al., 2011) .
Apolipoprotein E (ApoE), adiponectin (R&D Systems Europe, Ltd, Abingdon, United Kingdom), leptin (Diagnostics Biochem Canada Inc., Dorchester, Canada), and interleukin 6 (IL-6) levels (Sanquin Reagents, Amsterdam, The Netherlands) were determined using specific sandwich enzyme-linked immunosorbent assay (ELISA) (van Vlijmen et al., 1994; Mooijaart et al., 2006; Stijntjes et al., 2013) .
Alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) levels were measured using the NADH (with P-5′-P) methodology, albumin levels using the Bromcresol Purple methodology, and gamma-glutamyl transferase (γ-GT) levels using the L-gammaglutamyl-3-carboxy-4-nitroanilide substrate methodology (Sala et al., 2014) .
Creatine, folate and vitamin B12 levels were measured on the Abbott ci8200 (Architect, Abbott Laboratories, Illinois, USA), homocysteine levels were measured using a competitive immunoassay (Architect), while dehydroepiandrosterone sulfate (DHEAS) levels were measured with a delayed one-step immunoassay (Architect) .
For glucose, insulin, TSH, CRP, IL-6, FFA, triglyceride, ApoE, adiponectin, leptin, PTH, 25(OH) vitamin D, ALAT, albumin, ASAT, γ-GT, folate, vitamin B12, and DHEAS levels natural log transformed values were used for analyses due to non-normal distribution of the data, while triglyceride levels and LDL and HDL particle concentrations were batch corrected before analysis (Vaarhorst et al., 2011) .
Box 1 Biomarkers of healthy ageing
A biomarker of healthy ageing essentially (1) shows a change with chronological age, (2) discriminates individuals based on their familial propensity for longevity, and associates with (3) known health parameters and (4) morbidity and/or mortality in prospective studies (Deelen et al., 2013) . Ideally, the measurement of a biomarker (of healthy ageing) should be inexpensive, fast, and show minimal methodological variation within and between laboratories (Martin-Ruiz and von, 2014). There are three major classes of biomarkers of healthy ageing; (1) the pro-longevity class, for which a high level is considered healthy, (2) the anti-longevity class, for which a low level is considered healthy, and (3) the role-switching class, for which a level is considered anti-longevity at middle age and pro-longevity at advanced age, or vice versa (Moeller et al., 2014) .
Statistical analyses 2.3.1. Change with chronological age
To determine the change of serum parameters with chronological age, linear regression with the quantitative parameter as outcome, adjusted for gender, was performed in the combined group of LLS offspring and controls (n = 2342).
Discrimination based on familial propensity for longevity
To determine whether the serum parameters discriminate individuals based on their familial propensity for longevity and group (i.e. offspring of nonagenarian or control) as tested variable, linear regression with the quantitative biomarkers as outcome, adjusted for age, gender, and their interaction, was performed in the LLS offspring and controls.
Association with general health
To determine the effect of the serum parameters on general practitioner (GP)-reported general health, ordered logistic regression with GP-reported general health as outcome, adjusted for age and gender, was performed in the LLS offspring and controls. GP-reported general health was coded as 1 (excellent), 2 (good), 3 (poor), or 4 (very poor).
Association with mortality
To determine the effect of the serum parameters on mortality, prospective analysis with all-cause mortality as outcome, adjusted for age (middle age only) and gender, was performed in the combined group of LLS offspring and controls and separately in the LLS nonagenarians. After a mean follow-up time of 7.6 years (LLS offspring and controls) and 9.5 years (LLS nonagenarians), 4.6% (n = 108 (LLS offspring and controls)) and 92.7% (n = 862 (LLS nonagenarians)) of the individuals had died. We used a left-truncated Cox proportional hazards model to adjust for late entry into the data set according to age. It should be noted that not all serum parameters were available in the LLS nonagenarians.
GWAS-identified genetic variants
To determine the effect of biomarker of healthy ageing-associated genetic variants on human longevity, we performed a look-up of single nucleotide polymorphisms (SNPs) in the largest GWAS for human longevity reported to date (Deelen et al., 2014a) . SNPs were selected for the look-up if they showed a P b 5 × 10 −8 in the largest GWAS thus far performed for the identified biomarkers of healthy ageing. We subsequently determined if there was an enrichment of these genome-wide significant SNPs in the longevity GWAS dataset.
Analyses were performed using STATA/SE 11.2 (StataCorp LP, College Station, TX, USA). P-values were calculated using robust standard errors to account for sibship relations. For all analyses, P-values b 0.05 were considered nominal significant. After Bonferroni adjustment for the number of independent variables (estimated with matSpD (Cheverud, 2001; Li and Ji, 2005; Nyholt, 2004) ), a P b 1.90 × 10 − 4 (VeffLi = 27) was considered significant.
Results
The characteristics of the individuals from the LLS that were used in this study are shown in Table 1 . The study population consists of longlived siblings, their offspring, which are genetically enriched for the propensity for longevity, and controls. For the analyses in this study, we used 930 nonagenarians, 1602 offspring, and 740 controls.
Identification of biomarkers of healthy ageing meeting all four criteria
Using the LLS, we verified for 35 serum parameters routinely used in the clinic (see Table 1 for baseline characteristics) whether they met the four previously proposed criteria for biomarkers of healthy ageing (Deelen et al., 2013 ) (Materials and methods section 2.3.1-2.3.4 and Tables A.1-A.5). We identified three serum parameters meeting all four criteria for a biomarker of healthy ageing in the LLS; glucose, insulin, and (NMR-measured) triglycerides ( Fig. 1 and Table 2 ). For glucose and insulin, the direction of the observed associations matches between the different criteria and both parameters seem to be anti-longevity biomarkers, i.e. a low level is considered healthy. Triglycerides, on the other hand, seems to be a role-switching biomarker, i.e. anti-longevity at middle age and pro-longevity at advanced age (Table 2) .
Association of GWAS-identified genetic variants with human longevity
Next, we determined whether the identified biomarkers can be used in GWAS to identify genetic loci underlying human longevity. For all three parameters, we selected the SNPs that have previously been associated with the serum levels of these parameters at a genome-wide significant level in the largest available GWAS for that trait (Scott et al., 2012; Willer et al., 2013) . We subsequently performed a look-up of the selected genome-wide significant SNPs (n = 91) in the largest GWAS for longevity reported to date (Deelen et al., 2014a) and observed an enrichment of significant SNPs in our data (λ = 1.92, Fig. 2 ), i.e. 17 of the SNPs show a nominal significant association with longevity (P b 0.05, Table 3) , whereas 4 significant SNPs should be expected by chance. This corresponds to an odds ratio of 0.232 (95% CI 0.136-0.421, P = 3.07 × 10 −6
), based on 125,445 SNPs (out of the 2,470,845 tested) being nominal significant (P b 0.05) in the longevity GWAS dataset. One of these SNPs, rs4420638, representing the well-known TOMM40/APOE/APOC1 locus, was still significant after Bonferroni adjustment for multiple testing (P = 4.09 × 10 −21 ). This locus is one of the three loci previously associated with longevity at a genome-wide significant level, which shows the potential strength of our approach.
Discussion
By testing the four previously proposed criteria for biomarkers of healthy ageing (Deelen et al., 2013) in individuals from the LLS, we identified parameters involved in carbohydrate (glucose and insulin) and lipid metabolism (triglycerides) as biomarkers of healthy ageing. In addition, we showed that a relatively high proportion of the genetic variants previously associated with these parameters are also nominal significant in the largest GWAS for human longevity to date (Deelen et al., 2014a) .
All three biomarkers of healthy ageing identified in our study have previously been associated with at least one of the four criteria in other populations (Murray et al., 2013; Liu et al., 2013; Martin-Ruiz et al., 2011; Pyorala et al., 2000; Lara et al., 2015) . This further supports these parameters as biomarkers of healthy ageing. The proof of principle for our approach could be nicely demonstrated, since the identified biomarkers of healthy ageing had already been measured in many populations with genetic data, which allowed large GWAS to identify genetic loci associated with these parameters. However, even in the largest GWAS for these parameters to date the explained variance is only 4.8% (glucose), 1.2% (insulin) (Scott et al., 2012) and 2.1% (triglycerides) (Willer et al., 2013) , indicating that there is still a lot to discover. Fig. 1 . Overlap between serum parameters significantly associated with the biomarker of healthy ageing criteria in the Leiden Longevity Study.
Nonetheless, we were able to find an enrichment of significant genetic variants previously indicated to be involved in glucose, insulin and triglycerides regulation in the longevity GWAS dataset. This indicates that the genetic component underlying these traits may also contribute to human longevity.
Eight of the studied genetic loci are associated with multiple traits (Table 3 ), indicating that the identified biomarkers may share genetic pathways underlying healthy ageing. Interestingly, four of these loci, i.e. IRS1, RSPO3, TCF7L2, and FADS1-3, also showed a nominal significant association with longevity (P b 0.05). The FADS1-3 locus comprises 3 genes, FADS1, FADS2, and FADS3, which show a high sequence similarity and are thus likely arisen through gene duplication during evolution (Marquardt et al., 2000) . The genetic variants associated with glucose and triglycerides, i.e. rs174576 and rs174546, show cis-eQTL effects on FADS2 in blood, heart left ventricle, and esophagus muscularis, according to GTEx (http://www.gtexportal.org/home/). This indicates that the FADS2 gene may be the most important gene at the FADS1-3 locus concerning regulation of glucose and triglyceride levels and, potentially, healthy ageing. Genetic variation at the IRS1, RSPO3, TCF7L2, and FADS1-3 loci has also been associated with a range of metabolites, including fatty acid levels, but also with clinical phenotypes and diseases, such as waist-to-hip ratio, bone mineral density, resting heart rate, type 2 diabetes, and metabolic syndrome (http://www.ebi.ac.uk/gwas/) (Welter et al., 2014) . Hence, these loci seem to be important regulators of overall metabolism.
We have to acknowledge that there are some limitations of using the LLS to test all four criteria for a biomarker of healthy ageing. First, the age range in the LLS is limited due to the family-based design of the study, so the effects of a potential biomarker of healthy ageing below 50 years and between 70 and 90 years could not be determined. Second, the number of deceased individuals in the group of middle-aged offspring and controls is limited, although it was large enough to show a significant association of multiple parameters, including insulin, with mortality. In addition, we were able to test the association of most of the parameters with mortality in the long-lived individuals. Most of our findings were also supported by previous studies, which shows that the above mentioned limitations had limited effect on our results. To test all four criteria for a biomarker of healthy ageing in one study, the most optimal study design would be a population-based study in which a large group of families is followed during their entire lifetime and examined at multiple time points. However, since such a study is not yet available, the LLS may be used as an alternative.
In conclusion, we showed, by a proof of principle study, that parameters involved in carbohydrate (glucose, insulin) and lipid metabolism (triglycerides) are biomarkers of healthy ageing. The genetic loci associated with these parameters may be used in future studies in humans and animal models to identify mechanisms that promote healthy ageing.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.exger.2016.06.013. Table 2 Results of the tested serum parameters for the different criteria for biomarkers of healthy ageing. Table 3 Association of glucose-, insulin-, and triglyceride-associated genetic variants with survival to ages N90 years.
